AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35093147
Drug: Fetal gene
RxNorm normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fetal gene therapy trial
Trial: 35093163
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human growth hormone (rhGH) administered once daily for 12 weeks.
Trial: 35093164
Drug: Extended-release buprenorphine
RxNorm normalized name: Buprenorphine Extended-Release Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release buprenorphine (XRB)
Trial: 35093737
Drug: Multimodal pelvic
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal pelvic floor physiotherapy treatment (12 weekly sessions)
Trial: 35093737
Drug: Multimodal pelvic
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal pelvic floor physiotherapy treatment
Trial: 35093998
Drug: Valganciclovir treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valganciclovir treatment
Trial: 35094896
Drug: Stockholm3 test
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stockholm3 test with MRI and PSA ≥2 ng/ml
Trial: 35095867
Drug: Trastuzumab with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab with neoadjuvant chemotherapy
Trial: 35097222
Drug: Azithromycin and
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin and cefixime combination
Trial: 35098120
Drug: Improvisational dance
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Improvisational dance intervention (met twice weekly for 60 min for 8 weeks)
Trial: 35098170
Drug: Abiraterone acetate
RxNorm normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Abiraterone acetate plus prednisone (AAP) with androgen deprivation therapy (ADT)
Trial: 35098333
Drug: Bortezomib treatment
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib treatment (neurotoxic drug)
Trial: 35098345
Drug: Cetuximab (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetuximab (administered every 3 weeks, maximum of six doses) plus autologous expanded NK cells (infused the day after cetuximab administration)
Trial: 35099278
Drug: Loop, an
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loop, an Open-Source Automated Insulin Delivery System
Trial: 35099783
Drug: Non-PCI treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-PCI treatment pathway (control)
Trial: 35100081
Drug: Medications for
RxNorm normalized name: Medicated Shampoo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medications for opioid use disorder
Trial: 35100339
Drug: Langerhans-type dendritic
RxNorm normalized name: collagen type I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Langerhans-type dendritic cells (LCs) electroporated with CT7, MAGE-A3, and WT1 mRNA, 9 × 10^6 cells, administered as a priming immunization plus 2 boosters at 12, 30, and 90 days after ASCT.
Trial: 35100339
Drug: Standard lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Standard lenalidomide maintenance therapy started at 3 months after ASCT for all patients.
Trial: 35100411
Drug: Hyperferritinemia (≥500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperferritinemia (≥500 ng/mL) in 46 patients (26%)
Trial: 35100411
Drug: Hyperferritinemia (≥250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperferritinemia (≥250 ng/mL) in 90 patients (52%)
Trial: 35100411
Drug: Age- and
RxNorm normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Age- and sex-matched controls without infection, n = 50, median ferritin level 102.8 ng/mL (IQR 53.5-185.7)
Trial: 35101049
Drug: Cabazitaxel 20
RxNorm normalized name: cabazitaxel 20 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabazitaxel 20 mg/sqm
Trial: 35101049
Drug: Cabazitaxel 25
RxNorm normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cabazitaxel 25 mg/sqm
Trial: 35101049
Drug: Cabazitaxel (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabazitaxel (20 or 25 mg/sqm)
Trial: 35101175
Drug: Multi-lipid lowering
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-lipid lowering therapies (LLT)
Trial: 35103026
Drug: Platelet-rich plasma
RxNorm normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet-rich plasma (PRP) administration
Trial: 35105522
Drug: Heartech left
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heartech left ventricular partitioning device (LVPD) therapy
Trial: 35105587
Drug: ACL repair
RxNorm normalized name: hyaluronic acid Ophthalmic Gel [Optimend Corneal Repair]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACL repair and InternalBrace augmentation
Trial: 35105633
Drug: Celecoxib as
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib as an adjunct to treatment-as-usual
Trial: 35105633
Drug: Placebo as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo as an adjunct to treatment-as-usual
Trial: 35105642
Drug: Capillary blood
RxNorm normalized name: Capillary blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capillary blood sample antibody POCT targeting IgM and IgG against the receptor-binding domain of SARS-CoV-2
Trial: 35105722
Drug: Intravenous 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 120 mg belimumab
Trial: 35106698
Drug: Levodopa/carbidopa treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa/carbidopa treatment in 5 patients with dystonia
Trial: 35106962
Drug: Isatuximab monotherapy
RxNorm normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Isatuximab monotherapy
Trial: 35107750
Drug: Droxidopa (100-600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droxidopa (100-600 mg, 3 times daily)
Trial: 36849838
Drug: Inactivated COVID-19
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated COVID-19 vaccine
Trial: 35108379
Drug: DMARDs (Disease-Modifying
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMARDs (Disease-Modifying Anti-Rheumatic Drugs)
Trial: 35110167
Drug: Group art
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group art therapy using clay (6 sessions of 1.5 hours each)
Trial: 35110356
Drug: PSMA×CD3 bispecific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSMA×CD3 bispecific antibody (bsAb)
Trial: 35110417
Drug: Imatinib 400
RxNorm normalized name: imatinib 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib 400 mg daily with binimetinib 45 mg twice daily
Trial: 35111295
Drug: Switching to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switching to aripiprazole with 2-week dual administration and tapering off original agents (fast: n=38, slow: n=41)
Trial: 35111295
Drug: Baseline chlorpromazine
RxNorm normalized name: Chlorpromazine
DrugBank: Chlorpromazine (DB00477)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Baseline chlorpromazine equivalent dose in ARE+ group (405.8 ± 225.8 mg)
Trial: 35111828
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment with LVEF ≤55%
Trial: 35112104
Drug: Pharmaceutical venous
RxNorm normalized name: bushmaster venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical venous thromboembolism (pVTE) prophylaxis
Trial: 35112299
Drug: Dienogest therapy
RxNorm normalized name: Dienogest
DrugBank: Dienogest (DB09123)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dienogest therapy
Trial: 35112382
Drug: Fuzuloparib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fuzuloparib (150 mg single dose)
Trial: 35112928
Drug: Pcrit measurement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pcrit measurement during drug-induced sleep endoscopy (DISE)
Trial: 35113285
Drug: Sym013 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sym013 at 4 mg/kg once-weekly (changed to biweekly due to adverse events)
Trial: 35113285
Drug: Sym013 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sym013 at 15 mg/kg biweekly (Q2W)
Trial: 35113285
Drug: Sym013 (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sym013 (various doses)
Trial: 35113363
Drug: Etanercept (ETN)
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Etanercept (ETN) treatment for rheumatoid arthritis
Trial: 35113812
Drug: Fresolimumab (TGF-β
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fresolimumab (TGF-β neutralizing antibody)
Trial: 35113934
Drug: Interferon-γ (IFN-γ)
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon-γ (IFN-γ) administration
Trial: 35114169
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg intravenously every 3 weeks for 2 years or until disease progression
Trial: 35114404
Drug: Drugs suspected
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drugs suspected of inducing APS (14 drugs identified)
Trial: 35114814
Drug: 1-month dual
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1-month dual antiplatelet therapy after Synergy bioresorbable-polymer everolimus-eluting stent implantation
Trial: 35115195
Drug: AKS-452 22.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AKS-452 22.5 µg
Trial: 35115195
Drug: AKS-452 45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AKS-452 45 µg
Trial: 35115195
Drug: AKS-452 90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AKS-452 90 µg
Trial: 35115195
Drug: AKS-452 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AKS-452 (all doses)
Trial: 35118382
Drug: Gliadel 7.7
RxNorm normalized name: Gliadel 7.7mg Wafer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gliadel 7.7 mg implant (up to 8 wafers, 61.6 mg of carmustine)
Trial: 35118382
Drug: Gliadel 7.7
RxNorm normalized name: Gliadel 7.7mg Wafer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gliadel 7.7 mg implant
Trial: 35118821
Drug: Enzalutamide 160
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enzalutamide 160 mg once daily from day 8 to day 71
Trial: 35119037
Drug: Triptorelin 3.75
RxNorm normalized name: triptorelin 3.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triptorelin 3.75 mg once every 28 days for up to 24 weeks after conservative surgery for DIE
Trial: 35120446
Drug: First-line anti-TNF
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-line anti-TNF therapy for UC
Trial: 35120446
Drug: First-line anti-TNF
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-line anti-TNF therapy for CD
Trial: 35120446
Drug: First-line anti-TNF
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-line anti-TNF therapy for both UC and CD
Trial: 35120987
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of primary ciliary dyskinesia pulmonary exacerbations
Trial: 35121676
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy for Insomnia (CBT-I) delivered via telehealth, four-session protocol, details on dosage and duration not specified.
Trial: 35121899
Drug: Anti-CD20 treatment
RxNorm normalized name: Allogeneic anti-CD20 CAR T cells
DrugBank: PBCAR20A (DB17189)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-CD20 treatment
Trial: 35121950
Drug: ctDNA clearance
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ctDNA clearance during treatment
Trial: 35122060
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of radiation, ipilimumab, and nivolumab
Trial: 35122371
Drug: Endovascular thrombectomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular thrombectomy (EVT) with intravenous thrombolysis (IVT)
Trial: 35122700
Drug: LY2780301 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY2780301 plus weekly paclitaxel
Trial: 35123460
Drug: Three-dimensional corrective
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-dimensional corrective exercise therapy (TDCET)
Trial: 35123460
Drug: Generalized exercise
RxNorm normalized name: celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Generalized exercise therapy (Control Group)
Trial: 35123640
Drug: Steroids-Ruxolitinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroids-Ruxolitinib
Trial: 35123771
Drug: Navitoclax (ABT-737
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Navitoclax (ABT-737 analogue) monotherapy at 150 mg daily for 7-14 days, then increased to 250 mg daily
Trial: 35123771
Drug: Navitoclax (ABT-737
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Navitoclax (ABT-737 analogue) monotherapy
Trial: 35124411
Drug: Platinum doublet
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platinum doublet cytotoxic chemotherapy ± immunotherapy (Cohort 2)
Trial: 35124411
Drug: Post-treatment samples
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Post-treatment samples (all cohorts)
Trial: 35125401
Drug: Everolimus (2L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus (2L targeted therapy)
Trial: 35125401
Drug: Axitinib (2L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Axitinib (2L targeted therapy)
Trial: 35125401
Drug: Sunitinib (1L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib (1L targeted therapy)
Trial: 35126362
Drug: mRNA-1273 at
RxNorm normalized name: MRNA-1273 SARS-COV-2
DrugBank: Moderna COVID-19 Vaccine (DB15654)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA-1273 at a dose of 25 μg
Trial: 35126362
Drug: mRNA-1273 at
RxNorm normalized name: MRNA-1273 SARS-COV-2
DrugBank: Moderna COVID-19 Vaccine (DB15654)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA-1273 at a dose of 100 μg
Trial: 35127778
Drug: DHA algae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA algae oil supplement (3.15 g daily for 6 months)
Trial: 35128365
Drug: Sayana Press
RxNorm normalized name: garden cress sprout extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sayana Press injected every 4 months (3 treatment cycles) for 12 months
Trial: 35128529
Drug: High-dose split-virus
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose split-virus influenza vaccine (HD-SVV)
Trial: 35128529
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose split-virus influenza vaccine (SD-SVV)
Trial: 35128939
Drug: Extrafine Beclomethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extrafine Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrronium Bromide; specific dosage and duration not mentioned
Trial: 35129069
Drug: Gamitrinib, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gamitrinib, a mitochondria-targeted small molecule Hsp90 inhibitor
Trial: 35129214
Drug: Diazepam (3-day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (3-day treatment)
Trial: 37063970
Drug: Ticagrelor monotherapy
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor monotherapy after 3-month dual antiplatelet therapy (DAPT)
Trial: 35129374
Drug: Once-daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily oral cabotegravir 30 mg for 4 weeks
Trial: 35129374
Drug: Five 600-mg
RxNorm normalized name: HISTA-FIVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five 600-mg (3-mL) intramuscular cabotegravir LA injections at weeks 5, 9, 17, 25, and 33
Trial: 35129374
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral standard-of-care
Trial: 35129472
Drug: Intrathoracic implantation
RxNorm normalized name: INVESTIGATIONAL ANTI-NEOPLASTIC DRUGS INTRATHORACIC ORGANS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathoracic implantation of multidrug-eluting microdevices (IMDs) containing 12 chemotherapeutic agents, inserted intraoperatively and retrieved with the resected specimen.
Trial: 35129803
Drug: Ocrelizumab infusion
RxNorm normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ocrelizumab infusion after first-line immunotherapy
Trial: 35130292
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for acute leukaemia during pregnancy; specific details on dosage and duration not available.
Trial: 35130292
Drug: Successful treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Successful treatment of acute leukaemia prior to pregnancy; specific details on treatment not available.
Trial: 35130417
Drug: Chemotherapy maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy maintenance
Trial: 35130417
Drug: Chemotherapy maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy maintenance for hormone receptor-positive MBC patients
Trial: 35130417
Drug: Endocrine therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocrine therapy maintenance for hormone receptor-positive MBC patients
Trial: 35130417
Drug: Chemotherapy vs
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy vs Endocrine therapy maintenance
Trial: 35130943
Drug: Trametinib 2
RxNorm normalized name: trametinib 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trametinib 2 mg QD in Mild HD patients
Trial: 35130943
Drug: Trametinib 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trametinib 1.5 mg QD in Moderate HD patients
Trial: 35130943
Drug: Trametinib 1
RxNorm normalized name: trametinib 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trametinib 1 mg QD in Severe HD patients
Trial: 35130943
Drug: Trametinib (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trametinib (various doses)
Trial: 35131031
Drug: Assessment of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assessment of anti-S1/S2 antibody titer, IL-6, and CRP levels.
Trial: 35131040
Drug: Niraparib 300
RxNorm normalized name: niraparib 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niraparib 300 mg orally once daily until treatment discontinuation, death, or study termination.
Trial: 35131254
Drug: Topical ruxolitinib
RxNorm normalized name: ruxolitinib Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ruxolitinib applied twice daily for 8 weeks
Trial: 35131513
Drug: Direct oral
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct oral challenge for penicillin allergy delabeling
Trial: 35131875
Drug: PCA062 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCA062 at 3.6 mg/kg every 2 weeks
Trial: 35131875
Drug: PCA062 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCA062 at various dose levels (0.4 to 5.0 mg/kg every 2 weeks)
Trial: 35131903
Drug: Olaparib maintenance
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib maintenance monotherapy (300 mg orally twice daily until disease progression or unacceptable toxicity)
Trial: 35131903
Drug: Olaparib maintenance
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib maintenance monotherapy
Trial: 35132704
Drug: Lanreotide autogel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanreotide autogel (LAN) 120 mg/28 days for 1 year
Trial: 35133604
Drug: Patients without
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients without previous psychiatric treatment
Trial: 35133636
Drug: Aclidinium/formoterol 400/12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aclidinium/formoterol 400/12 µg twice daily
Trial: 35133982
Drug: Chemotherapy without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemotherapy without CIPN